GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Future 3-5Y Total Revenue Growth Rate

TOVX (Theriva Biologics) Future 3-5Y Total Revenue Growth Rate : N/A (As of May. 11, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Theriva Biologics's Future 3-5Y Total Revenue Growth Rate is N/A.


Competitive Comparison of Theriva Biologics's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Theriva Biologics's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

Theriva Biologics  (AMEX:TOVX) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Theriva Biologics Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics Business Description

Industry
Traded in Other Exchanges
N/A
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics Headlines

From GuruFocus

Q2 2019 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2023 Theriva Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2018 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2022 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2021 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2021 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Synthetic Biologics Inc Operational Update Call Transcript

By GuruFocus Research 02-15-2024

Q2 2022 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2020 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q4 2021 Synthetic Biologics Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024